Weber R R, McCoy C E, Ziemniak J A, Frederickson E D, Goldberg L I, Murphy M B
Department of Pharmacological and Physiological Science, University of Chicago, Illinois 60637.
Br J Clin Pharmacol. 1988 Jan;25(1):17-21. doi: 10.1111/j.1365-2125.1988.tb03276.x.
1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.
